Sensory integration therapy for children with autism and sensory processing difficulties: the SenITA RCT

Elizabeth Randell,1* Melissa Wright,1 Sarah Milosevic,1 David Gillespie,1 Lucy Brookes-Howell,1 Monica Busse-Morris,1 Richard Hastings,2 Wakunyambo Maboshe,1 Rhys Williams-Thomas,1 Laura Mills,1 Renee Romeo,3 Nahel Yaziji,3 Anne Marie McKigney,4 Alka Ahuja,4 Gemma Warren, Eleni Glarou,1,5 Sue Delport6† and Rachel McNamara1†

1Centre for Trials Research, Cardiff University, Cardiff, UK
2Centre for Educational Development, Appraisal, and Research (CEDAR) University of Warwick, Coventry, UK
3Institute of Psychiatry Psychology and Neuroscience, King’s College London, London, UK
4Aneurin Bevan University Health Board, Newport, UK
5Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK
6School of Healthcare Sciences, Cardiff University, Cardiff, UK

*Lead and corresponding author RandellE@cardiff.ac.uk
†Joint last/senior author

Declared competing interests of authors: David Gillespie was an associate member of the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) General Committee (2019 to September 2021) and is a member of the NIHR HTA Commissioning Committee (September 2021 to present).

Disclaimer: This report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.

Published June 2022
DOI: 10.3310/TQGE0020
Scientific summary

Background

Approximately 1–2% of children have a diagnosis of autism in the UK, of whom ≥ 90% also experience at least moderate sensory processing difficulty (SPD), which can have an impact on their daily life and well-being. Addressing SPDs using specific interventions, which are typically delivered by occupational therapists, could lead to improvements across behavioural, social and educational domains. The National Institute for Health and Care Excellence (NICE) guidelines on the management of and support for children and young people with autism highlight parental perceptions of unmet need for occupational therapy (OT) input to address sensory and functional difficulties. However, despite unmet need, there is insufficient evidence to recommend any one therapeutic approach. NICE has recommended further research to establish whether or not sensory integration therapy (SIT) improves SPDs in children with autism across a range of contexts. Several systematic reviews have identified only two randomised studies of SIT. Both reported good fidelity of delivery; however, the intervention protocols were variable in terms of dose and delivery period, and both studies are limited by small convenience samples, poorly described comparators and only short-term follow-up. The SenITA (SENsory Integration Therapy for sensory processing difficulties in children with Autism spectrum disorder) randomised controlled trial (RCT) tested the clinical effectiveness and cost-effectiveness of SIT, which is a manualised play-based intervention delivered by occupational therapists to address specific sensory difficulties. SIT was compared with usual care for children aged 4–11 years with autism and SPDs. Outcomes, which were assessed at 6 and 12 months, included behavioural, functional and socialisation outcomes, quality of life, well-being and cost-effectiveness.

Objectives

- To describe current usual care in trial regions and clearly differentiate this from the trial intervention.
- To evaluate the clinical effectiveness of manualised SIT for SPDs in young children with autism in terms of impact on behavioural problems and adaptive skills, socialisation, carer stress, quality of life and cost-effectiveness.
- To explore recruitment, retention, fidelity of delivery, adherence, acceptability, adverse effects and contamination in a process evaluation conducted alongside the main trial.

Methods

Design

The SenITA trial was a two-arm individual RCT of SIT for children with autism and SPDs.

Setting and population

Children with autism and SPDs were recruited from child and adolescent mental health and paediatric services, schools and social services and via self-referral. Therapy was delivered in clinics meeting manualised fidelity criteria. Inclusion criteria were as follows: diagnosis of autism spectrum disorder or a related condition (e.g. social communication disorder), in and likely to remain in mainstream primary education for the duration of the trial (and aged 4–11 years), definite/probable SPDs and carer consent/child assent. Exclusion criteria were as follows: receipt of current/previous SIT and receipt of current applied behaviour analysis therapy.
**Intervention and comparator**

The intervention comprised Ayres Sensory Integration® therapy delivered in 26 1-hour sessions over 26 weeks [i.e. two sessions per week for 10 weeks (intensive phase), followed by two sessions per month for 2 months and then one telephone session per month for 2 months (tailoring phase)]. The comparator was usual care, which was defined as awaiting services or receiving sensory-based intervention not meeting fidelity criteria for sensory integration. Pre-trial focus groups and interviews carried out with parents/carers and therapists allowed us to define usual care in trial regions and, to some extent, across the UK more broadly.

**Sample size and randomisation**

A total of 138 participants were randomised in a 1 : 1 ratio based on 90% power, a 5% significance level and a moderate standardised effect size of 0.5 (inflated by 20% for dropout). Online randomisation utilised random permuted blocks stratified by region and severity of SPD.

**Costs and outcomes**

Sensory processing difficulties were assessed at screening and at 6 months. An Autism Diagnostic Observation Schedule was carried out at baseline to characterise the sample in terms of autism symptoms only and not for diagnostic purposes. Outcomes were measured at 6 and 12 months post randomisation. The primary outcome was irritability/agitation (as measured by the corresponding Aberrant Behavior Checklist subscale), indicative of challenging behaviour, at 6 months. Secondary outcomes included other problem behaviours, adaptive behaviours and functioning, socialisation, carer stress and quality of life.

**Statistical analyses**

The main analyses were modified intention to treat, with those participants providing outcome data included. A full intention-to-treat analysis comprised all participants in the group to which they were randomised, with missing outcome data imputed using multiple imputation. This analysis set served as a sensitivity analysis to the primary outcome. Finally, a complier-average causal effect population comprised participants with outcome data in the group to which they were randomised, accounting for those participants who received the intervention as intended. This analysis set also served as a sensitivity analysis to the primary outcome. Primary outcome analysis compared trial arms by fitting linear regression to irritability/agitation scores 6 months post randomisation, adjusting for baseline scores, recruitment region, severity of SPD, and sex of the child. Findings are reported as adjusted mean differences with associated 95% confidence intervals (CIs) and p-values. Most secondary outcomes were analysed similarly.

We explored differential intervention effects on the primary outcome by age, severity of SPD and comorbid conditions [i.e. attention deficit hyperactivity disorder (ADHD), intellectual disability (ID) and other neurodevelopmental/genetic condition], site, region and sex of the child. Our primary model was extended by including subgroup × trial arm interaction terms. Subgroup effects were also explored for carer stress scores 6 months post randomisation. We used multiple imputation to investigate the potential influence of missing data on the primary outcome. Sensitivity analyses adjusted for intervention receipt, impact of the COVID-19 pandemic and the correlated nature of repeated observations within individuals. Models adjusted for baseline measures and variables balanced at randomisation. We planned to conduct mediation analyses to explore whether or not any intervention effects at 12 months were mediated through an effect on sensory sensitivities post intervention. Agreement between parent- and teacher-reported Aberrant Behavior Checklist – irritability (ABC-I) scores was assessed using a Bland–Altman plot. Performance on carer-reported goals was compared between sessions 1 and 24 using paired t-tests for participants allocated to the intervention only.
Cost-effectiveness
A cost-effectiveness evaluation assessed intervention, NHS, social and education service costs, as well as carer costs. The main cost-effectiveness measure was the incremental cost per point improvement in irritability/agitation at the primary outcome time point.

Internal pilot and process evaluation
An internal pilot with progression criteria assessed recruitment, retention and whether or not usual care differed from expected provision. A process evaluation examined recruitment, retention, fidelity of delivery, adherence, acceptability, adverse effects and contamination. Therapist and carer interviews conducted as part of the process evaluation explored barriers to and facilitators of participation, adherence, therapeutic relationship, mechanisms of change, sensory processing deficit, engagement in activities and contamination. Interview and focus group data were double coded and analysed thematically.

Results

Internal pilot and process evaluation
Targets for recruitment, retention and other key parameters used to estimate sample size were met, maintaining 90% power at the primary analysis time point. Usual care was significantly different from the intervention offered as part of the trial, was delivered with good fidelity and adherence, and there was no evidence of significant contamination in the comparator arm or that participants allocated to SIT received meaningful intervention via other routes. No adverse effects were reported.

Trial procedures and outcome measures were acceptable to carers, and therapists generally found involvement in the trial to be a positive experience. Carers in the intervention arm reported high levels of satisfaction and benefit of SIT, although no statistically significant change in carer stress was observed. Both carers and therapists tended to report improvements in well-being and daily functioning, although there is no evidence to suggest that these effects were maintained following completion of therapy. Therapists’ experience of delivering sensory integration was generally positive, and most felt that it could offer benefit to some children, depending on their need.

Clinical effectiveness
There were, however, no statistically significant effects of the intervention on the primary outcome of irritability/agitation at 6 months [mean score: usual care 18.8 [standard deviation (SD) 10.48]; intervention 18.5 (SD 9.33)]. Adjusted mean difference between groups on the ABC-I at 6 months post randomisation was 0.40 (95% CI -2.33 to 3.14; p = 0.77). The correlation between baseline and 6-month scores was 0.698 (95% CI 0.585 to 0.784). Teacher-rated irritability/agitation scores at 6 months, where available, were typically lower than carer ratings [i.e. the mean difference between carer-rated and teacher-rated scores at 6 months was 10.28 (SD 14.48), with a 95% limit of agreement of -18.12 to 38.68]. There was strong evidence of a difference between the two measures (p < 0.001), indicating that, on average, carer ratings were higher. Conclusions drawn from primary analyses were unaffected by sensitivity analyses accounting for missing data, intervention receipt (i.e. dose) or the COVID-19 pandemic. No evidence of meaningful intervention effects was found at 6 or 12 months across behavioural, adaptive functioning, socialisation, carer stress, health utility or quality-of-life measures. Carer-rated goal performance and satisfaction data were available for a subset of participants allocated to receive the intervention. There was strong evidence of an increase in scores on both measures between session 1 and session 24 [i.e. a mean change in score of 2.75 (95% CI 2.14 to 3.37) for carer-rated performance and of 3.34 (95% CI 2.63 to 4.40) for satisfaction; p < 0.001].

There was a differential effect of the intervention on irritability/agitation at 6 months by region (intervention arm × South England = 9.77, 95% CI 4.04 to 15.49; p = 0.001). The results also indicate a differential effect of the intervention on the primary outcome at 6 months by sex of child (intervention × female = 6.42,
95% CI 0.00 to 12.85; \( p = 0.050 \) and those with ADHD (intervention × ADHD = –6.77, 95% CI –13.55 to –0.01; \( p = 0.050 \)). Similarly, there was a differential effect of the intervention on carer stress at 6 months by region (intervention arm × South England = 7.01, 95% CI 0.45 to 13.56; \( p = 0.04 \)) and presence of other neurodevelopmental or genetic conditions (intervention × neurodevelopmental/genetic condition present = –9.53, 95% CI –18.08 to –0.98; \( p = 0.030 \)). No differential effects were observed at 6 months for severity of SPD, general comorbidity, ID or other specific neurodevelopmental or genetic condition.

**Cost-effectiveness**
The delivery of SIT incurred significant additional costs. When intervention costs were not included in total NHS/Personal Social Services (PSS) costs, NHS/PSS costs of care for usual care-only participants were significantly higher than NHS/PSS costs for SIT participants. Economic evidence suggests, however, that SIT has a low probability of being a cost-effective option compared with usual care.

**Conclusions**
The SenITA trial was a robust evaluation of the clinical effectiveness and cost-effectiveness of sensory integration for behavioural, functional and quality-of-life outcomes. Targets for recruitment, retention and other key parameters used to estimate sample size were met, and usual care for the trial population was described in detail and found to be significantly different from the sensory integration intervention offered as part of the trial. SIT was delivered with fidelity and adherence was generally high, with no evidence of significant contamination. No adverse effects were reported. The population recruited were probably representative of children within autism services, although girls and minority ethnic boys are likely to be under-represented in both the current study and the wider population of children diagnosed with autism. Acceptability was high among carers and therapists, in terms of both study participation and intervention receipt and delivery, and therapists generally felt that SIT could offer benefit to some children, depending on their needs.

No main intervention effects were observed, and sensitivity analyses did not alter the interpretation of results. Subgroup analyses suggest that SIT may work better for boys and those with a comorbid diagnosis of ADHD. However, these subgroup analyses were exploratory analyses and, although the results were statistically significant and indicative of clinical importance, were not powered to detect effects. Therefore, the results may be reflective of multiple testing and need to be confirmed in a subsequent study. Carer-rated goal performance and satisfaction did increase significantly with exposure to the intervention, and carers and therapists generally reported improvements in well-being and functioning following intervention receipt. However, there is no evidence to suggest any improvements were maintained in the longer term, that is, following completion of therapy. Economic evaluation also suggests that SIT is not cost-effective compared with usual care.

**Strengths and limitations**
A key strength was that the trial was powered to determine the clinical effectiveness and cost-effectiveness of SIT for children with autism and SPDs. The intervention was delivered with good fidelity and adherence and was acceptable to families and therapists, and no adverse effects were reported. The inclusion of longer-term outcome assessment is also a strength, as previous studies have assessed outcomes post intervention only. The SenITA trial has also provided a detailed description of usual care for children with autism and SPDs and has highlighted the gap between available services and the types of intervention and support that are most valued by carers.

There are a number of limitations of the current trial, however, including variability of intervention provision across regions (i.e. NHS delivery in Wales and delivery by private practitioners in England), underestimation of intervention delivery costs (i.e. time allowed for initial assessment and clinical reasoning) and delay for some participants allocated to intervention in receiving therapy (although sensitivity analyses do not suggest any differential effect). In addition, there was an error in
administration of the Vineland Adaptive Behavior Scales, creating a ceiling effect, although, similarly, given the pattern of results across other outcomes, it is not likely that this would have altered the interpretation of the results. Interpretation of the positive effect of therapy on carer-reported goal performance is also limited in that it was not possible to measure this outcome in the control arm, as families were not generally under the care of OT services.

Taken together, the results suggest that SIT did not demonstrate clinical benefit across a range of outcomes (i.e. behavioural, functional, social, quality of life and well-being) over and above standard care for young children with autism and SPDs. Although statistically significant intervention effects were observed for some subgroups (i.e. boys and children with comorbid ADHD), these findings should be considered as hypothesis-generating only and require further confirmation. It is also likely that SIT is effective for individualised (carer-reported) performance goals, although it was not possible to compare goals set in the intervention arm with standard care in the current trial, and it is not clear whether or not perceived improvements are maintained in the longer term.

**Trial registration**

This trial is registered as ISRCTN14716440.

**Funding**

This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 26, No. 29. See the NIHR Journals Library website for further project information.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.014

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 15/106/04. The contractual start date was in January 2017. The draft report began editorial review in June 2021 and was accepted for publication in March 2022. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health and Care Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care.

Copyright © 2022 Randell et al. This work was produced by Randell et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editor-in-Chief of HSDR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Consultant in Public Health, Delta Public Health Consulting Ltd, UK

Dr Peter Davidson  Interim Chair of HTA and EME Editorial Board. Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Senior Adviser, Wessex Institute, University of Southampton, UK

Dr Catriona McDaid  Reader in Trials, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Professor Helen Roberts  Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk